|
piclidenoson
|
Clinical candidate for RA (Phase 2 NCT01034306).
|
Piclidenoson (CF101) is being evaluated in a number of clinical trials, as a potential therapy for several autoimmune-inflammatory disorders (rheumatoid arthritis, Phase 2I, NCT02647762 [ 328] ...
|
|
adalimumab
[
(Drugs.com) ]
|
Anti-TNFα monoclonal antibody therapy approved for RA
|
Used in the management of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease and plaque psoriasis. In 2015 both the EMA and the FDA approved the use of adalimumab as a treatment for hidradenitis suppurativa, a chronic skin disease that causes abscesses and scarring on the skin. In July 2016, the FDA expanded adalimumab approval as the first non-corticosteroid drug available for use as a treatment for non-infectious intermediate, posterior and panuveitis (forms of autoimmune-driven inflammation of the uvea)- results from Phase 3 clinical trial NCT01138657 are published in [ 143] ...
|
|
|
doramapimod
|
Phase 2 clinical candidate for RA.
|
Doramapimod (as research code BIRB 796) has been assessed in Phase 2 clinical trials for plaque-type psoriasis and rheumatoid arthritis (RA). Addition ...
|
|
|
tamatinib
|
This is the active metaboloite of fostamatinib and may have clinical utility in RA.
|
Tamatinib is a potential drug for treatment of the inflammation associated with and causing bronchial asthma resulting from allergen-induced airway hy ...
|
|
|
infliximab
[
(Drugs.com) ]
|
Used in combination with methotrexate to reduce production of anti-infliximab antibodies. However, if infliximab is rendered ineffective, other anti-T ...
|
Used in the management of rheumatoid arthritis (in combination with ), ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease [324] ...
|
|
|
sarilumab
[
(Drugs.com) ]
|
FDA approved therapeutic for RA (May 2017).
|
Sarilumab was granted FDA approval as a treatment for moderate to severe active RA in May 2017 (with EMA approval granted in June 2017), following evaluation in several clinical trials, either as a monotherapy ( eg NCT02121210) or in combination with other drugs such as , , and .
Click here to link to ClinicalTrials.gov's listing of Phase 3 sarilumab trials. A Phase 2 study for non-infectious uveitis (NCT01900431) has been completed, whereas a Phase 2 extension study (NCT01118728) for ankylosing spondylitis was terminated.
In June 2024 FDA approval of sarilumab was expanded to include use as a treament for active polyarticular juvenile idiopathic arthritis (pJIA).
SARS-CoV-2 and COVID-19: Sarilumab has been evaluated for potential to reduce exaggerated inflammation in hospitalised patients with COVID-19. The Phase 2/3 clinical trial (NCT04315298) did not meet its primary or secondary endpoints in these patients and the trial was terminated. An Italian trial also failed to find mortality benefit [59] ...
|
|
|
etanercept
[
(Drugs.com) ]
|
Approved drug for severe active RA.
|
|
|
|
CR6086
|
CR6086 is a Phase 2 clinical candidate for RA- see NCT03163966
|
A proof-of-concept clinical trial evaluating CR6086 plus in RA patients with early stage disease and who are DMARD-naive is underway- see NCT03163966 ...
|
|
|
remtolumab
|
Phase 2 clinical candidate for RA- see NCT02433340
|
Remtolumab has reached Phase 2 clinical trial for rheumatoid arthritis and psoriatic arthritis.
|
|
|
maraviroc
[
(Drugs.com) ]
|
Maraviroc-induced CCR5 blockade failed to show clinical efficacy in RA clinical trial.
|
Maraviroc is approved for use in combination antiretroviral treatment of patients infected with CCR5-tropic HIV-1 virus. Maraviroc-induced CCR5 blockade was investigated for action in treating rheumatoid arthritis, but with discouraging clinical trial results. Other CCR5 antagonists ( and ) have also proven ineffective in RA clinical trials [303] ...
|
|
|
ancriviroc
|
Ancriviroc-induced CCR5 blockade failed to show clinical efficacy in RA.
|
|
|
|
indomethacin
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Indomethacin is used widely for various inflammatory conditions, for which the drug's analgesic and antipyretic properties are beneficial. Such condit ...
|
|
|
gimsilumab
|
Phase 1 clinical candidate for RA. A single-dose of 10 mg/kg produced a clinically meaningful effect, evaluated as a decreased disease activity score ...
|
|
|
|
acalabrutinib
[
(Drugs.com) ]
|
Phase 2 clinical trial in RA completed (NCT02387762)
|
Having already received FDA Orphan Drug Designation and Breakthrough Therapy Designation for mantle cell lymphoma (MCL: a rare and fast-growing type of non-Hodgkin lymphoma), in August 2017 the FDA granted priority review for acalabrutinib's New Drug Application (NDA), based on results from a Phase 2 study in relapsed/refractory MCL ( NCT02213926). This resulted in full FDA approval in October 2017 ( link to FDA announcement). This approval is for the treatment of MCL patients who have received at least one prior therapy. For a list of all registered acalabrutinib trials, link here to ClinicalTrials.gov. In November 2019, FDA approval was expanded to include treatment of CLL or SLL, following evaluation in trials including NCT02475681 and NCT02970318; clinial trial results in patients with CLL are reported in [ 287] ...
|
|
|
ozoralizumab
|
Ozoralizumab has completed proof-of-concept Phase II clinical trial in RA (NCT00959036- in patients on a background of methotrexate)
|
|
|
|
fosdagrocorat
|
Phase 2 clinical trial in RA (NCT00938587) has been completed.
|
Results of a Phase 2 clinical trial evaluating fosdagrocorat in patients with rheumatoid arthritis (RA) have been published [ 300] ...
|
300
|
|
evobrutinib
|
Phase 2 clinical candidate for RA- see NCT03233230
|
Evobrutinib was evaluated in clinical trials for rheumatoid arthritis, systemic lupus erythematosus and relapsing-remitting multiple sclerosis. A full list of evobrutinib trials registered with ClinicalTrials.gov is available by clicking here ...
|
|
|
zimlovisertib
|
Phase 2 clinical candidate for RA- see NCT02996500.
|
A Phase 2 clinical trial evaluating PF-06650833 in patients with rheumatoid arthritis (RA) and an inadequate response to (NCT02996500 ...
|
190
|
|
Galapagos MAPKAPK5 inhibitor D
|
Failed Phase 2 clinical candidate for methotrexate-refractory RA.
|
|
344
|
|
GW406381
|
Phase 3 clinical candidate for RA- see NCT00113308.
|
GW406381 has completed Phase 3 clinical evaluation in knee osteoarthritis [ 27] ...
|
|
|
MK-0359
|
Completed Phase 2 clinical evaluation in RA- see NCT00482417
|
MK-0359 exhibited clinical efficacy in a Phase 2 study in asthma patients ( NCT00482898), but caused gastrointestinal adverse effects [ 196] ...
|
|
|
baricitinib
[
(Drugs.com) ]
|
Approved drug for moderate to severe RA.
|
The EMA granted baricitinib marketing authorisation in February 2017, for the treatment of rheumatoid arthritis (RA). This approval covered doses of either 2 or 4 mg. Phase 3 trial results reporting significant clinical improvement in patients who's symptoms had failed to respond to other disease-modifying antirheumatic drugs (DMARDs) were published in [ 110] ...
|
|
|
CFZ533
|
Phase 1 clinical candidate for RA- see completed trial NCT02089087
|
CFZ533 is being evaluated in clinical trials as a therapy for some autoimmune conditions and for preventing/reducing solid organ transplant rejection. Click here ...
|
|
|
AZD9567
|
Phase 2 clinical candidate for RA- see NCT03368235
|
AZD9567 has reached Phase 2 clinical trial for rheumatoid arthritis in which it is being compared to (see NCT03368235 ...
|
|
|
CZ415
|
CZ415 exhibits potent preclinical anti-inflammatory activity in vivo, and is under consideration for rheumatoid arthritis.
|
|
36
|
|
CH-4051
|
CH-4501 completed Phase 2 trial in RA- see NCT01116141
|
CH-4051 completed Phase 2 clinical trial in patients with rheumatoid arthritis ( NCT01116141 ...
|
|
|
MK-0873
|
Completed Phase 2 trial for RA- see NCT00132769
|
MK-0873 has completed Phase 2 clinical evaluation in rheumatoid arthritis ( NCT00132769 ...
|
|
|
PF-04905428
|
Failed to show clinical efficacy in Phase 3 trial.
|
A Phase 3 clinical trial in patients with rheumatoid arthritis (RA: NCT00628095) has been completed. Results showed PF-04905428 (CE-224,535) was not effective in treating RA [ 301] ...
|
|
|
CCL2
|
CCL2 is implicated in the pathogenesis of RA.
|
|
|
|
niflumic acid
[
(Drugs.com) ]
|
COX2 inhibition affords this drug anti-inflammatory activity, used clinically for the treatment of RA.
|
Used in the treatment of rheumatoid arthritis. There is no information regarding approval for clinical use of this drug on the US FDA or European Medi ...
|
|
|
mefenamic acid
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Used in the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, inflammation, fever and pain.
|
|
|
ibuprofen
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Ibuprofen is used widely for its analgesic and antipyretic actions.
|
|
|
diclofenac
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Diclofenac is used to treat pain or inflammation caused by osteoarthritis and rheumatoid arthritis, but is also used to treat other conditions which b ...
|
|
|
prednisolone
[
(Drugs.com) ]
|
Glucocorticoid drug used to treat many inflammatory condtions including RA.
|
This drug used as an antiinflammatory or immunosuppressive agent and is indicated for the treatment of various inflammatory pathologies, including acu ...
|
|
|
triamcinolone
[
(Drugs.com) ]
|
Glucocorticoid drug used to treat many inflammatory condtions including RA.
|
Triamcinolone is used for its antiinflammatory or immunosuppressive actions in many conditions. For example, oral triamcinolone is used to treat condi ...
|
|
|
celecoxib
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Celecoxib is used to treat osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms. It is also used to reduce th ...
|
|
|
rofecoxib
[
(Drugs.com) ]
|
Withdrawn from US market due to safety concerns.
|
A non-steroidal anti-inflammatory drug previously used in the treatment of rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, acture migraine ...
|
|
|
valdecoxib
[
(Drugs.com) ]
|
Withdrawn from US market due to safety concerns.
|
Prior to manufacturer's withdrawl from the US and EU markets, valdecoxib was approved to treat osteoarthritis, rheumatoid arthritis and primary dysmen ...
|
|
|
etoricoxib
[
(Drugs.com) ]
|
Selective COX2 inhibitor approved for the treatment of many inflammatory conditions including RA.
|
Used in the treatment of rheumatoid arthritis, osteoarthritis, chronic lower back pain, ankylosing spondylitis, acute pain and gout. There is no infor ...
|
|
|
flurbiprofen
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Flurbiprofen is approved to treat the pain and inflammation associated with rheumatic diseases and other musculoskeletal disorders, as well as dysmeno ...
|
|
|
ketoprofen
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with ...
|
|
|
methotrexate
[
(Drugs.com) ]
|
Approved drug for RA.
|
Anti-tumour agent used in the treatment of acute lymphocytic leukemia (ALL), meningeal leukemia, non-Hogkin's lymphoma, breast, lung and head and neck cancers. Also indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole, and in the treatment of autoimmune conditions including severe psoriasis and rheumatoid arthritis. The first oral methotraxate solution (Xatmep®) was FDA approved in April 2017 for the treatment of ALL and polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients. A 2017 a paper reported that a combination of methotrexate with leflunomide relieves the immune defects and ameliorates symptoms of rheumatoid arthritis [ 356] ...
|
|
|
fenoprofen
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Fenoprofen is used to treat inflammatory conditions such as rheumatoid- and osteo-arthritis in addition to being used for pain relief.
|
|
|
IL-17A
|
Approved therapy for RA.
|
|
|
|
BAFF
|
BAFF is a drug target for RA.
|
|
|
|
naproxen
[
(Drugs.com) ]
|
Approved NSAID used for many inflammatory conditions including RA.
|
Used in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, and acute gout. Also used in pain relief ...
|
|
|
sulindac
[
(Drugs.com) ]
|
Approved drug for RA.
|
For acute relief or long term use in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder and acute gouty arthritis.
|
|
|
tofacitinib
[
(Drugs.com) ]
|
Approved drug for RA.
|
Tofacitinib was intiailly approved for the treatment of rheumatoid arthritis. Marketed formulations contain tofacitinib citrate (PubChem CID 10174505). In Feb 2016 Xelanj XR® was FDA approved as the first once-daily oral JAK inhibitor for rheumatoid arthritis. In June 2018, FDA approval was expanded to include treatment of patients with moderate to severe ulcerative colitis (UC), subsequent to results from the Phase 3 OCTAVE studies, in which treatment of UC patients with tofacitinib met all primary endpoints and induced significant disase remission [ 230, 254, 278] ...
|
|
|
IL-1 receptor antagonist
|
A recombinant, non-glycosylated version of this protein is marketed as rheumatoid arthritis drug called Anakinra
|
|
|
|
IL-27
|
Anti- and pro-inflammatory activities of IL-27 have been reported by a number of RA studies.
|
|
|
|
leflunomide
[
(Drugs.com) ]
|
A DMARD approved for active RA.
|
Used to treat active rheumatoid arthritis (improve physical function and slow progression), prevention of acute/chronic rejection following organ tran ...
|
|
|
cipemastat
|
An MMP1 clinical candidate which failed Phase 1 clinical trial in RA.
|
This compound was being investigated as a treatment for rheumatoid arthritis [ 133] ...
|
|
|
BMS-561392
|
An investigational ADAM17 inhibitor with potential to reduce TNFα production in TNF-driven conditions such as RA.
|
Potential treatment for overproduction of TNF alpha, such as rheumatoid arthritis (phase 2 trial) or inflammatory bowel disease [ 123] ...
|
|
|
certolizumab pegol
[
(Drugs.com) ]
|
An anti-TNFα therapy approved for RA.
|
Used to treat rheumatoid arthritis (RA) and Crohn's disease [ 41] ...
|
|
|
golimumab
[
(Drugs.com) ]
|
An anti-TNFα therapy approved for RA.
|
Used in adults with various inflammatory conditions [ 357] ...
|
|
|
rituximab
[
(Drugs.com) ]
|
An anti-CD20 therapy approved for RA.
|
Used to treat CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and several autoimmune conditions (severe active, DMARD/TNF inhibitor-refracrtory rheumatoid arthritis; severe, active granulomatosis with polyangiitis (Wegener's, GPA); microscopic polyangiitis (MPA)). Rituximab is also used to suppress antibody-mediated rejection in living-donor kidney recipients prior to an ABO-incompatible transplant [ 92, 201] ...
|
|
|
abatacept
[
(Drugs.com) ]
|
Approved drug for RA.
|
Used to treat moderate to severe rheumatoid arthritis and juvenile rheumatoid arthritis. In July 2017, FDA approval was extended to include treatment of active psoriatic arthritis. A Phase 2 clinical trial ( NCT00505375) has been completed, evaluating the ability of abatacept to stop autoimmune destruction of any remaining active β cells in patients recently diagnosed with type 1 diabetes mellitus- see [ 197] ...
|
|
|
anakinra
[
(Drugs.com) ]
|
An IL-1RA mimetic approved to treat RA that is resistant to other anti-rheumatic drugs.
|
Anakinra is used to treat the symptoms of moderate to severe rheumatoid arthritis and may also help slow the progress of the disease. This drug is usu ...
|
|
|
pateclizumab
|
Pateclizumab failed to show clinical efficacy in patients with active RA after 12 weeks of treatment.
|
Pateclizumab (as research code MLTA3698A) has completed Phase 2 clinical trial in patients with active rheumatoid arthritis. In this trial ( NCT01225393) MLTA3698A plus a DMARD was directly compared with plus a DMARD, and results were reported by Kennedy et al. (2014) [164] ...
|
164
|
|
prednisone
[
(Drugs.com) ]
|
Approved drug for RA.
|
Used to treat a wide variety of inflammatory conditions.
|
|
|
azathioprine
[
(Drugs.com) ]
|
Approved drug for RA.
|
Used to reduce organ rejection in transplant patients and to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, lupus erythemato ...
|
|
|
diflunisal
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
Dislusinal is used to treat moderate pain, and responsive inflammatory conditions including osteo- and rheumatoid arthritis.
|
|
|
etodolac
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA and OA.
|
Etodolac is indicated for acute or long-term use in osteo- and rheumatoid arthritis.
|
|
|
meclofenamic acid
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
Used to treat muscular pain, arthritis and dysmenorrhea. There is no information regarding approval for clinical use of this drug on the US FDA websit ...
|
|
|
meloxicam
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
This drug is used to treat pain and inflammation associated with osteo- and rheumatoid arthritis. In January 2025 the FDA approved a combination of me ...
|
|
|
nabumetone
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
Used to treat pain and inflammation associated with osteo- and rheumatoid arthritis.
|
|
|
oxaprozin
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
Used to treat pain or inflammation caused by osteo- and rheumatoid arthritis.
|
|
|
penicillamine
[
(Drugs.com) ]
|
An immunosuppressant used to manage RA.
|
As a chelating agent penacillamine is used to remove copper from tissues (in patients whose copper-transporting ATPase, ATP7B, is non-functional causi ...
|
|
|
piroxicam
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
Used to treat rheumatoid and osteoarthritis, primary dysmenorrhoea and postoperative pain.
|
|
|
suprofen
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
Used as an antiarthritic and to treat inflammations of the eye. Marketing authorisation has been discontinued in the US, but other national approval a ...
|
|
|
tolmetin
[
(Drugs.com) ]
|
NSAID used to treat the pain and inflammation of RA.
|
Used to relieve the symptoms of osteo- and rheumatoid arthritis.
|
|
|
AZD5672
|
Failed clinical candidate for RA (showed no significantl efficacy).
|
AZD5672 was tested as a potential treatment for rheumatoid arthritis, however, the compound failed to show efficacy in clinical trial, and development ...
|
|
|
AZ11657312 (salt free)
|
Experimental compound.
|
|
|
|
mavrilimumab
|
Clinical candidate therapeutic for RA (Phase 2 studies completed).
|
A phase 2 clinical trial ( NCT01712399) of mavrilimumab in adult rheumatoid arthritis (RA) patients has been completed (May 2017). In these patients mavrilimumab produced a rapid and prolonged reduction in interleukin-6 production which is indicative of suppression of tissue inflammation. Further development in RA has been discontinued, however Kiniksa Pharmaceuticals are actively evaluating mavrilimumab (which they have re-coded as KPL-301) in a Phase 2 trial in patients with giant cell arteritis (GCA) [ 171] ...
|
|
|
dilmapimod
|
Phase 2 candidate for RA, but has not progressed further.
|
SB-681323 has been assessed to Phase 2 in clinical trial for indications including chronic obstructive pulmonary disease, rheumatoid arthritis and neuropathic pain, although there are no currently active trials (as of Nov 2014). Click here ...
|
|
|
talmapimod
|
Phase 2 candidate for RA, but has not progressed further.
|
Talmapimod has been assessed in several completed Phase 2 clinical trials for myelodysplastic syndromes and active rheumatoid arthritis. Click here ...
|
|
|
AZD9056
|
Reached Phase 2 clinical evaluation in RA, but development was discontinued.
|
AZD9056 was developed for the treatment of inflammatory conditions such as rheumatoid arthritis (RA), chronic obstructive pulmonary disease (COPD) and Crohn’s disease. Phase 2 trial NCT00520572 ...
|
|
|
spebrutinib
|
Completed Phase 2 clinical evaluation in RA (see NCT01975610).
|
Spebrutinib has been granted orphan drug designation by the EMA (using the chemical name n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide benzenesulfonic acid salt) for the treatment of B-cell chronic lymphocytic leukemia (CLL). Spebrutinib (as research code CC-292) has been compared with placebo as a co-therapy with for active rheumatoid arthritis, in completed clinical trial NCT01975610 ...
|
|
|
BMS-582949
|
Reached Phase 2 clinical evaluation in RA and plaque psoriasis, but development has not progressed.
|
BMS-582949 was assessed in Phase 2 clinical trials for atherosclerosis ( NCT00570752 ...
|
|
|
sirukumab
|
Phase 3 clinical candidate for RA (see NCT01856309).
|
Phase 3 clinical trials assessing sirukumab for RA have been completed or are still ongoing (Oct 2017). Click here to link to ClinicalTrials.gov's listing of Phase 3 sirukumab trials. Other trials are collecting data in additional inflammatory conditions including lupus nephritis [ 275] ...
|
|
|
tabalumab
|
Tabalumab was a clinical candidate therapeutic for RA.
|
Tabalumab progressed to Phase 3 clinical evaluation in patients with SLE [ 306] ...
|
|
|
secukinumab
[
(Drugs.com) ]
|
Phase 3 study in RA was terminated (see NCT01770379).
|
Secukinumab is approved by the US FDA for the treatment of plaque psoriasis. Secukinumab also met its clinical endpoints in Phase 2I clinical trial for ankylosing spondylitis ( NCT01649375) [ 13] ...
|
|
|
decernotinib
|
Developed as a potential treatment for RA, but no evidence of progress in clinical development.
|
Decernotinib reached Phase 3 clinical trial as a potential treatment for rheumatoid arthritis (RA), but development appears to have been terminated, a ...
|
|
|
peficitinib
[
(Drugs.com) ]
|
Phase 3 clinical candidate for RA.
|
Peficitinib was first approved as a treatment for rheumatoid arthritis in 2019 [ 207] ...
|
|
|
vobarilizumab
|
Phase 2 clinical candidate for RA (see NCT02518620).
|
Vobarilizumab (as research code ALX-0061) has reached Phase 2 clinical trial. See NCT02437890 ...
|
|
|
itacitinib
|
Phase 2 study NCT01626573 in RA has been completed.
|
INCB039110 is being assessed in Phase 2 clinical trials as a potential treatment for indications such as rheumatoid arthritis (RA), post essential thrombocythemia myelofibrosis, chronic plaque psoriasis and non-small cell lung cancer (NSCLC). Phase 3 trials in chronic graft-versus-host disease are also underway. Click here ...
|
|
|
amelubant
|
No progress in development beyond Phase 2 trial in RA.
|
Amelubant (BIIL 284) reached Phase 2 clinical trial for inflammatory conditions including chronic obstructive pulmonary disease (COPD), bronchial asth ...
|
|
|
SC-67655
|
Experimental compound with predicted application in RA.
|
|
|
|
lenzilumab
|
Clinical candidate for RA (maximum Phase 2).
|
Lenzilumab has completed Phase 2 clinical trial for uncontrolled asthma, whereas a Phase 2 study in patients with inadequately controlled rheumatoid arthritis has been terminated. A Phase 1 trial in patients with previously treated chronic myelomonocytic leukemia (CMML) is ongoing [ 250] ...
|
|
|
VRT-043198
|
Experimental compound with predicted application in inflammatory skin conditions and RA.
|
|
|
|
eldelumab
|
No progress beyond Phase 2 trial.
|
Eldelumab has been evaluated in Phase 2 clinical trials for rheumatoid arthritis [ 349] ...
|
|
|
MK-0812
|
Phase 2 trial NCT00542022 in RA was completed- no further progress recorded.
|
MK-0812 has completed a Phase 2 efficacy, tolerability and safety clinical trial in patients with rheumatoid arthritis ( NCT00542022 ...
|
|
|
MRL-367
|
Experimental compound with predicted application in RA.
|
|
|
|
MRL-248
|
Experimental compound with predicted application in RA.
|
|
|
|
timolumab
|
Completed Phase 1 clinical trial NCT00851240.
|
Timolumab (with research code BTT1023) is being evaluated in Phase 2 clinical trial NCT02239211 ...
|
|
|
PLX5622
|
Phase 1b clinical trial completed (see NCT01329991).
|
A Phase 1b study of PLX5622 in RA patients receiving therapy has been completed- see NCT01329991 ...
|
|
|
cabiralizumab
|
Phase 1 in RA terminated and development discontinued.
|
Cabiralizumab (research code FPA008) is in early stage clinical trials for solid tumours and rheumatoid arthritis (RA). Click here ...
|
|
|
GSK583
|
Experimental compound with predicted application in RA.
|
|
|
|
clazakizumab
|
No progress beyond Phase 2 trial.
|
Phase 2 clinical trials in patients with active rheumatoid arthritis ( NCT01373151, results reported in [ 341] ...
|
|
|
briakinumab
|
Clinical development for RA has been terminated.
|
Results from a Phase 2 clinical trial ( NCT00292396) evaluating briakinumab in patients with moderate to severe chronic plaque psoriasis are reported in [ 167] ...
|
|
|
fezakinumab
|
Completed Phase 2 trial for RA (see NCT00883896).
|
Fezakinumab (ILV-094) has reached Phase 2 for atopic dermatitis ( NCT01941537 ...
|
|
|
TG6-129
|
Probe compound for experimental use.
|
|
|
|
fenebrutinib
|
Phase 2 clinical candidate for RA (see NCT02983227 and NCT02833350).
|
GDC-0853 was reported to be well tolerated with no dose-limiting adverse events in phase 1 studies in healthy volunteers [ 135] ...
|
|
|
TAK-715
|
An experimental TNFα-reducing compound, developed for anti-inflammatory activity.
|
|
|
|
deflazacort
[
(Drugs.com) ]
|
Approved corticosteroid that can be prescribed for RA.
|
Deflazacort can be prescribed for many inflammatory conditions including asthma, rheumatoid arthritis, Crohn's disease, juvenile chronic arthritis, idiopathic thrombocytopenic purpura, polymyalgia rheumatica, systemic lupus erythematosus and ulcerative colitis. More recently approved by the FDA as a treatment for Duchenne muscular dystrophy [ 122] ...
|
|
|
BMS-817399
|
BMS-817399 was a clinical candidate for RA that reached Phase 2 clinical trial
|
BMS-817399 failed to show clinical efficacy in a 12 week Phase 2 proof-of-concept trial in patients with moderate to severe RA.
|
|
|
CHMFL-BTK-11
|
A pharmacological tool suitable for investigating BTK mediated signaling in RA.
|
|
|
|
GSK2982772
|
Clinical candidate in RA.
|
GSK2982772 is in Phase 2 clinical trials in psoriasis ( NCT02776033 ...
|
|
|
upadacitinib
[
(Drugs.com) ]
|
FDA approved drug for RA (August 2019).
|
Upadacitinib (ABT-494) completed successful Phase 3 clinical evaluation for rheumatoid arthritis (RA) [ 98, 222, 295] ...
|
|
|
atacicept
|
Atacicept was in clinical development for the treatment of RA.
|
Atacicept was investigated for clinical efficacy in a range of autoimmune conditions e.g. SLE [ 117] ...
|
|
|
PFK15
|
Postulated to inhibit fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritis.
|
|
359
|
|
CP-195543
|
CP-195543 was a Phase 2 clinical candidate for RA (see NCT00424294). Development was discontinued due to its poor tolerability profile and high discon ...
|
|
|
|
rabeximod
|
Phase 2 evaluation as an adjunct to methotrexate therapy in RA has been completed- see NCT00525213
|
|
|
|
BMS-986142
|
Phase 2 clinical candidate for RA- see NCT02638948.
|
Efficacy of BMS-986142 will be evaluated in rheumatoid arthritis patients in Phase 2 clinical study NCT02638948. ...
|
|
|
tregalizumab
|
Tregalizumab failed to show clinical efficacy in Phase 2 trial (NCT01999192), and development was discontinued.
|
Phase 2 clinical trial ( NCT01999192) in patients with active RA and an inadequate response to , was terminated early as the therapy failed to show clinical efficacy above methotrexate control [326] ...
|
326
|
|
branebrutinib
|
Phase 1 candidate for RA- all studies completed to date (March 2018) have been conducted in healthy subjects, NOT in RA patients (e.g. NCT03131 ...
|
BMS-986195 has completed Phase 1 trials in healthy subjects but not yet in patients with RA. As of August 2019 there has been no further development o ...
|
|
|
pelubiprofen
|
Results from a Phase 3 clinical trial that compared 6 weeks treatment with pelubiprofen to celecoxib treatment, indicate that this novel drug is as ef ...
|
Pelubiprofen has completed Phase 3 clinical evaluations for the management of the inflammation and pain associated with rheumatoid arthritis ( NCT01781702 ...
|
40
|
|
andecaliximab
|
Phase 2 clinical trial in RA patients has been terminated (see NCT02862574).
|
Andecaliximab (GS-5745) is being evaluated in various clinical trials (max Phase 3) for cancers and inflammatory conditions. Click here ...
|
|
|
fostamatinib
[
(Drugs.com) ]
|
Phase 3 clinical candidate for RA.
|
Fostamatinib (as the disodium hexahydrate salt) received FDA approval for the treatment of chronic immune thrombocytopenia (ITP) [ 239] ...
|
180
|
|
pamapimod
|
Phase 2 clinical studies evaluating pamapimod (RO4402257) in RA patients either as a monotherapy (NCT00303563), or as an adjunct to methotrexate thera ...
|
Pamapimod reached Phase 2 clinical evaluation as an immunomodulator for rheumatoid arthritis, but development was terminated due to a lack of clinical efficacy, either as a monotherapy, or as an adjunct to methotrexate [ 5, 45] ...
|
5
|
|
chloroquine
[
(Drugs.com) ]
|
|
Chloroquine is one of the antimalarials listed in the World Health Organization's Model List of Essential Medicines, with its recommended use restrict ...
|
|
|
hydroxychloroquine
[
(Drugs.com) ]
|
|
Hydroxychloroquine is used to treat or prevent malaria, and is also used to treat discoid lupus erythematosus and rheumatoid arthritis.
|
|
|
tocilizumab
[
(Drugs.com) ]
|
Tocilizumab was the first humanized mAb to be developed against human IL-6 receptors, and is now an approved therapeutic for RA.
|
Tocilizumab had been approved in Japan in 2005 as a treament for giant lymph node hyperplasia (Castleman's disease) [ 209] ...
|
|
|
tibulizumab
|
Phase 1 clinical trial NCT01925157 in RA has been completed.
|
Tibulizumab (LY3090106) is a Phase 1 clinical candidate for Sjögren's syndrome and rheumatoid arthritis. Click here ...
|
|
|
namilumab
|
Phase 2 clinical candidate for RA: namilumab has demonstrated clinical efficacy in methotexate and anti-TNF therapy-resistant RA patients
|
Phase 2 evaluation in a 12 week study has demonstrated the clinical efficacy effected by inhibiting macrophage activity via targeting of GM-CSF in patients with rheumatoid arthritis [ 309] ...
|
309
|
|
IL-6
|
IL-6 is known to drive arthritic inflammation and bone destruction in RA. mAbs against both the IL-6 ligand and its receptor (IL-6R) are now approved ...
|
|
|
|
elsubrutinib
|
Clinical candidate for RA
|
Elsubrutinib has progressed to Phase 2 evaluations to determine efficacy in trial subjects with rheumatoid arthritis or systemic lupus erythematosus.
|
|
|
ritlecitinib
[
(Drugs.com) ]
|
Phase 2 clinical candidate for RA (NCT02969044). In this study oral treatment with ritlecitinib (200 mg once daily) was well tolerated, and was associ ...
|
PF-06651600 completed Phase 2 clinical trials for rheumatoid arthritis and ulcerative colitis and was advanced to Phase 2b/3 in alopecia areata patients (the ALLEGRO study). Click here to link to ClinicalTrials.gov's full list of PF-06651600 trials. In June 2023 the FDA approved ritlecitinib to treat severe alopecia areata, based on positive efficacy results from the ALLEGRO study [ 169] ...
|
270
|
|
ABBV-3373
|
Investugational treatment for RA
|
ABBV-3373 is being evaluated for safety and efficacy in patients with moderate to severe rheumatoid arthritis (RA) [ 31, 51] ...
|
|
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License